Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

NCT ID: NCT02175680

Last Updated: 2023-04-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-04-16
• Study Completion Date: 2015-02-02

Brief Summary

This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy.

Consenting subjects will be shifted from their combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks. Total treatment duration with PRO 140 will be 14 weeks with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment, and one week overlap at the end of the treatment in subjects who do not experience virologic failure.

Detailed Description

This study is a Phase 2b, multi-center study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in patients who are stable on combination antiretroviral therapy.

Patient enrollment will be staggered in this study to facilitate adequate safety monitoring. A lead cohort will include 12 subjects. Enrollment of additional 28 subjects will not be initiated until it is approved by the independent Data Monitoring Committee (DMC).

Consenting patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks. Total treatment duration with PRO 140 will be up to 14 weeks with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience Virologic Failure.

PRO 140 will be administered as a 350 mg subcutaneous injection weekly for up to 14 weeks. Study participants will be monitored for viral rebound on a weekly basis following initiation of PRO 140 monotherapy and will re-initiate their previous antiretroviral regimen if plasma HIV-1 RNA levels rise above 400 copies/ml on two consecutive blood draws at least 3 days apart.

The study will have three phases: Screening Phase, Treatment Phase and Follow-up Phase.

The primary objective is to assess efficacy of PRO 140 monotherapy for the maintenance of viral suppression following substitution of antiretroviral therapy in patients who are stable on combination antiretroviral therapy.

The secondary objective of the trial is to assess the clinical safety and tolerability parameters following substitution of antiretroviral therapy in patients who are stable on combination antiretroviral therapy.

Conditions

HIV; Human Immunodeficiency Virus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

PRO 140

PRO 140 350mg weekly SQ injection.

Group Type: EXPERIMENTAL

PRO 140

Intervention Type: DRUG

CCR5 Antagonist

Historical data

Intervention Type: OTHER

Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).

Interventions

PRO 140

CCR5 Antagonist

Intervention Type: DRUG

Historical data

Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).

Intervention Type: OTHER

Other Intervention Names

PRO 140 350mg

Eligibility Criteria

Inclusion Criteria

1. Males and females, age ≥18 years

2. Exclusive CCR5-tropic virus at Screening Visit as determined by Trofile™ DNA Assay

3. On stable antiretroviral therapy for last 12 months

4. Subject has two or more potential alternative antiretroviral regimen options to consider.

5. No documented detectable viral loads (HIV-1 RNA <50 copies/ml) within the last 12 months prior to Screening Visit

6. Nadir CD4 cell count of >200 cells/mm3

Exclusion Criteria

1. CXCR4-tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ DNA Assay at the Screening Visit

2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg)

3. Any acquired immune deficiency syndrome (AIDS)-defining illness according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition

4. Prior use of any entry, attachment, CCR5 co-receptor, or fusion inhibitor, including PRO 140.

5. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amarex Clinical Research

OTHER

Sponsor Role: collaborator

CytoDyn, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jacob Lalezari, MD

Role: PRINCIPAL_INVESTIGATOR

Locations

Quest Clinical Research

San Francisco, California, United States

Countries

United States

References

Chang XL, Reed JS, Webb GM, Wu HL, Le J, Bateman KB, Greene JM, Pessoa C, Waytashek C, Weber WC, Hwang J, Fischer M, Moats C, Shiel O, Bochart RM, Crank H, Siess D, Giobbi T, Torgerson J, Agnor R, Gao L, Dhody K, Lalezari JP, Bandar IS, Carnate AM, Pang AS, Corley MJ, Kelly S, Pourhassan N, Smedley J, Bimber BN, Hansen SG, Ndhlovu LC, Sacha JB. Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species. PLoS Pathog. 2022 Mar 31;18(3):e1010396. doi: 10.1371/journal.ppat.1010396. eCollection 2022 Mar.

Reference Type: DERIVED

PMID: 35358290 (View on PubMed)

Other Identifiers

PRO 140_CD 01

Identifier Type: -

Identifier Source: org_study_id